Berger Franklin M's Form 4 filing
Retension Pharmaceuticals, Inc.RTSN · filed Oct 13, 2026
- Accession no.
- 0001213900-26-109155
- Filed
- Oct 13, 2026, 6:10 PM ET
- Trade date
- Oct 13, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $120.0K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Berger Franklin MCIK 0001273885 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 13, 2026 | Common Stock | CConversionAcquired | +12,517 | –F1 | – | 12,517 | Direct | |
| Oct 13, 2026 | Common Stock | PPurchaseAcquired | +10,000 | $12.00 | +$120,000 | 10,000 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 13, 2026 | Common Stock | CConversionDisposed | −12,517 | –F1 | – | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.